TORONTO - Optimind Pharma Corp. (CSE:OMND ('Optimind' or the 'Company') announced its commencement of trading on the CSE (Canadian Securities Exchange) under ticker symbol 'OMND'.

Optimind specializes in prescribing medical cannabis and other alternative treatments for various medical ailments. Optimind prides itself on providing quality education and health care to patients. Medical cannabis has quickly become one of the most prescribed medications in Canada due to its efficacy and safety profile, which remains the primary business of the clinic.

Optimind is also an emerging provider of psychedelic therapies at its clinic, helping people suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine assisted treatment and other psychedelic enhanced psychotherapy modalities.

Optimind is also a 40% shareholder of Manitari Pharma. Manitari Pharma has submitted an application to Health Canada for a Controlled Substances Dealer's Licence for Psilocybin Research Purposes.

'The public listing of Optimind represents a significant milestone in the growth of our company. It's an important step that will help facilitate our mission to provide psychedelic-assisted therapies for the public and improve their quality of life,' commented Tomas Sipos, Chief Executive Officer at Optimind.

'Optimind is on it's way to becoming a leader in psychedelic-assisted therapy that will provide patients throughout North America with choices that promote mental, physical, and spiritual wellness. I'm supportive and enthusiastic to be a part of this exciting development and opportunity,' commented The Hon. Tony Clement, Chair of the Advisory Board at Optimind.

'Manitari Pharma's vision is to incorporate cutting-edge science with experience from shamanic traditions to create wellness psilocybin products used to treat mental illness and create spiritual well-being. As an Indigenous group out of Kanesatake Quebec, we are delighted our partners at Optimind are now trading on the CSE. This is vital in expanding our mission in ensuring the future mental health of First Nations and the global community at large,' said Anna Freeman, Chief Executive Officer of Manitari Pharma.

'Psychedelic-assisted therapy has the power to drastically transform people's lives around the world. At Optimind, our mission is to help people live life fully again through our treatment,' commented Dr. Michael Hart, Chief Operating Officer at Optimind.

About Optimind

Optimind specializes in prescribing medical cannabis and other alternative treatments for various medical ailments. Optimind prides itself on providing quality education and health care to patients. Medical cannabis has quickly become one of the most prescribed medications in Canada due to its efficacy and safety profile, which remains the primary business of the clinic.

Optimind is also an emerging provider of psychedelic therapies at its clinic, helping people suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine assisted treatment and other psychedelic enhanced psychotherapy modalities. For more information, visit www.Optimindpharma.com.

Caution regarding Forward Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. Persons', as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19;risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Contact:

Tomas Sipos

Chief Executive Officer

E: info@optimindpharma.com

(C) 2022 Electronic News Publishing, source ENP Newswire